ombrabulin Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.   Wikipedia

Chemistry

  • SMILES: COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
  • InChIKey: IXWNTLSTOZFSCM-YVACAVLKSA-N
  • Mol. Mass: 402.45
  • ALogP: 2.15
  • ChEMBL Molecule:
    ombrabulin  
More Chemistry

Pharmacology

Alternative names

ac 7700 | ac-7700 | ave8062 | n-(2-methxoy-5-(2-(3,4,5-trimethoxyphenyl)vinyl)pheyl)-serinamide hydrochloride | ombrabulin

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Sarcoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue